Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 17, 2024

BUY
$47.98 - $54.4 $15,977 - $18,115
333 Added 3.05%
11,250 $610,000
Q4 2023

Jan 12, 2024

BUY
$48.48 - $57.85 $42,129 - $50,271
869 Added 8.65%
10,917 $560,000
Q3 2023

Oct 17, 2023

SELL
$57.89 - $64.73 $14,646 - $16,376
-253 Reduced 2.46%
10,048 $583,000
Q2 2023

Jul 05, 2023

BUY
$63.71 - $70.74 $122,960 - $136,528
1,930 Added 23.06%
10,301 $658,000
Q1 2023

Apr 04, 2023

BUY
$65.71 - $74.53 $95,345 - $108,143
1,451 Added 20.97%
8,371 $580,000
Q4 2022

Feb 01, 2023

BUY
$68.48 - $81.09 $76,012 - $90,009
1,110 Added 19.1%
6,920 $497,000
Q3 2022

Jan 03, 2023

BUY
$0.13 - $76.84 $299 - $177,193
2,306 Added 65.81%
5,810 $413,000
Q2 2022

Aug 12, 2022

BUY
$72.62 - $79.98 $35,075 - $38,630
483 Added 15.99%
3,504 $270,000
Q1 2022

Apr 06, 2022

BUY
$61.48 - $73.72 $185,731 - $222,708
3,021 New
3,021 $221,000
Q3 2021

Nov 01, 2021

SELL
$59.17 - $69.31 $181,770 - $212,920
-3,072 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$61.91 - $67.42 $7,800 - $8,494
-126 Reduced 3.94%
3,072 $205,000
Q1 2021

May 11, 2021

SELL
$59.34 - $66.74 $54,948 - $61,801
-926 Reduced 22.45%
3,198 $202,000
Q4 2020

Feb 12, 2021

SELL
$57.74 - $65.43 $53,640 - $60,784
-929 Reduced 18.39%
4,124 $256,000
Q3 2020

Nov 09, 2020

BUY
$57.43 - $63.64 $9,533 - $10,564
166 Added 3.4%
5,053 $304,000
Q2 2020

Aug 05, 2020

BUY
$54.82 - $64.09 $43,801 - $51,207
799 Added 19.55%
4,887 $287,000
Q1 2020

May 07, 2020

SELL
$46.4 - $67.43 $25,195 - $36,614
-543 Reduced 11.73%
4,088 $228,000
Q4 2019

Feb 06, 2020

BUY
$49.21 - $64.19 $227,891 - $297,263
4,631 New
4,631 $297,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Cedar Brook Financial Partners, LLC Portfolio

Follow Cedar Brook Financial Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cedar Brook Financial Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cedar Brook Financial Partners, LLC with notifications on news.